Please Download Flash

Browse News by Year:
  RSS
News Highlights:

Ultragenyx Appoints Eric Yuen, MD as Chief Medical Officer and Senior Vice President

May 1, 2013 - Ultragenyx Pharmaceutical Inc., a biotechnology company focused on the development of treatments for rare and ultra-rare genetic disorders, today announced it has appointed Eric Yuen, MD as its Chief Medical Officer and Senior Vice President. In this new role, Dr. Yuen will provide leadership and direction to Clinical Operations, Clinical Affairs, Clinical Sciences, Data Management/Biometrics, and Drug Safety. He will report to Dr. Emil Kakkis, CEO, and will serve on the Senior Management Team. View Full Article

Tetraphase Pharmaceuticals Announces Exercise of Underwriters' Option to Purchase Additional Shares in its Initial Public Offering

April 12, 2013 - Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced that the underwriters for its initial public offering have exercised their over-allotment option and purchased an additional 797,792 shares in the offering. The sale of the additional shares, together with the shares sold at the initial closing of the offering, brings the total number of shares sold in the offering to 11,512,078 resulting in aggregate proceeds of $80.6 million, before underwriting discounts, commissions and expenses. Tetraphase's common stock is listed on the NASDAQ Global Market under the symbol "TTPH." All of the shares in the offering were offered by Tetraphase Pharmaceuticals.

View Full Article

Ultragenyx Initiates Novel Disease Monitoring Program for Hereditary Inclusion Body Myopathy

April 8, 2013 - Ultragenyx Pharmaceutical Inc. today announced the launch of a unique Disease Monitoring Program (DMP) for Hereditary Inclusion Body Myopathy (HIBM), also known as GNE Myopathy. The goal of the HIBM-DMP is to improve the body of knowledge about this rare disease and its typical course. This novel program is being conducted in partnership with the University of Newcastle's TREAT-NMD organization, a global neuromuscular physician network. View Full Article

Tetraphase Pharmaceuticals Announces Pricing of Initial Public Offering

March 20, 2013 - Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced the pricing of its initial public offering of 10,714,286 shares of common stock at a price to the public of $7.00 per share, less underwriting discounts and commissions. Tetraphase's common stock is expected to begin trading on the NASDAQ Global Market under the symbol "TTPH" on March 20, 2013. View Full Article

Blueprint Medicines Announces First Collaboration with Wellcome Trust Sanger Institute And Massachusetts General Hospital Cancer Center

March 19, 2013 - Blueprint Medicines, a company harnessing the understanding of the molecular blueprint of cancer to develop personalized, highly-selective cancer therapies, today announced its first collaboration with Wellcome Trust Sanger Institute and the Massachusetts General Hospital Cancer Center. The collaboration will focus on a large collection of Blueprints next-generation, highly-selective kinase inhibitor compounds, utilizing the Sanger Institute and Mass. Generals extensive human cancer cell line panel that will enable discoveries of novel cancer targets and new cancer dependencies. View Full Article

IRONWOOD PHARMACEUTICALS APPOINTS EDWARD OWENS TO BOARD OF DIRECTORS

March 4, 2013 - Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced the appointment of Edward Owens to its board of directors. Mr. Owens is a recently retired partner, portfolio manager and global industry analyst with Wellington Management Company, LLP. View Full Article

US HealthVest Gains $36 Million in Financing

March 4, 2013 - US HealthVest, LLC announced today that it has raised $36 million through co-founders Richard Kresch, MD and Polaris Partners to acquire and develop psychiatric facilities with a focus on specialized, high-quality patient care. Co-investors include Fidelity Biosciences; George Conrades, Chairman of Akamai Technologies; Trevi Health Ventures; Jonathan Bush, CEO of athenahealth; Carl Byers, former CFO of athenahealth; and members of the US HealthVest management team.

View Full Article

SIMPLEE AND LIAZON TO CREATE FIRST BENEFITS EXCHANGE WITH EXPENSE MANAGEMENT TOOLS

February 26, 2013 - Simplee and Liazon today announced a partnership to provide all Liazon Bright Choices Exchange users with integrated access to the Simplee healthcare expense management platform. This partnership forms the first private benefits exchange that allows consumers to both select a personalized benefits portfolio and then track and manage their healthcare expenses throughout the year.

View Full Article

Blueprint Medicines Welcomes David Schenkein, M.D., to its Board of Directors

February 25, 2013 - Blueprint Medicines, a company harnessing the understanding of the molecular blueprint of cancer to develop personalized, highly-selective cancer therapies, today announced the addition of David Schenkein, M.D., chief executive officer of Agios Pharmaceuticals, to its board of directors. View Full Article

Ed Park, athenahealth COO, Joins Kyruus Board of Directors

February 12, 2013 - Kyruus, a leading healthcare Big Data company, announced today that Ed Park, an original team member and current COO of athenahealth, has joined the companys Board of Directors. Park had been an early investor in Kyruus along with athenahealth co-Founder and CEO, Jonathan Bush. In his expanded role with Kyruus, Park will bring his deep technical and market expertise to the company as it continues to expand its work with leading hospital systems.

View Full Article

Tetraphase Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering

February 12, 2013 - Tetraphase Pharmaceuticals, Inc., today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering.

View Full Article

IRONWOOD PHARMACEUTICALS PROMOTES DR. MARK CURRIE TO SENIOR VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, AND PRESIDENT OF R&D

February 11, 2013 - Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced the promotion of Mark Currie, Ph.D. to senior vice president, chief scientific officer (CSO), and president of research and development (R&D). View Full Article

Final Ruling on Physician Payment Sunshine Act Emphasizes the Need for Kyruus Physician-Industry Interactions Solutions

February 5, 2013 - The Centers for Medicare and Medicaid Services (CMS) recently announced the final ruling of the Physician Payment Sunshine Act outlining the specific details of a database that will list payments made to physicians or teaching hospitals by applicable manufacturers of drugs, devices, biological, or medical supplies. The increased transparency is intended to reduce the potential for conflict of interest that physicians or teaching hospital could face as a result of their relationships with manufacturers. The data will be released publicly on September 30th, 2014 through an electronic reporting system.

View Full Article

Ultragenyx Announces In-Licensing of Clinical-Stage Product Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorders

January 10, 2013 - Ultragenyx Pharmaceutical Inc., a biotechnology company focused on the development of treatments for rare and ultra-rare genetic disorders, announced that it has in-licensed rights for triheptanoin, a promising treatment for long-chain fatty acid oxidation disorders (FAOD), from Baylor Research Institute in Dallas, TX. Triheptanoin is intended as a substrate replacement therapy to restore deficient intermediates in the mitochondria and to enable energy metabolism in patients with FAOD and potentially other genetic metabolic disorders. View Full Article

Kyruus Raises $11M Series B to Accelerate the Rapid Growth of its Physician Network Management Solutions

January 2, 2013 - Kyruus, a leading healthcare Big Data company, today announced the closing of an $11M Series B financing. The investment was led by Lux Capital, with participation from Fidelity Biosciences as well as existing investors Venrock and Highland Capital Partners. The financing brings the total amount raised by Kyruus to $19.6M since its inception in 2010.
View Full Article

Ultragenyx Raises $75 Million in Oversubscribed Crossover Financing

December 20, 2012 - Ultragenyx Pharmaceutical Inc., a biotechnology company focused on the development of treatments for rare and ultra-rare genetic disorders, today announced the successful completion of a $75 million Series B round financing led by Adage Capital Partners, LP. Joining Adage as new investors in this financing are mutual funds and separate account clients advised by T. Rowe Price Associates, Inc., Jennison Associates LLC (on behalf of clients), funds and accounts under management by subsidiaries of BlackRock, Inc., Sanofi-Genzyme BioVentures , Shire plc and additional blue chip public market funds. Existing investors, TPG Biotech, Fidelity Biosciences, HealthCap and Pappas Ventures also participated in the transaction. View Full Article

IRONWOOD AND FOREST ANNOUNCE U.S. AVAILABILITY OF LINZESS (Linaclotide)

December 17, 2012 - Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) announced today that LINZESS (linaclotide) is now available in pharmacies throughout the United States. The U.S. Food and Drug Administration (FDA) recently approved LINZESS as a once-daily oral capsule for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).

LINZESS is the first and only FDA-approved guanylate cyclase-C (GC-C) agonist and acts locally in the intestine. For the first time in over six years, a new prescription option is available for adults with these disorders.

Visit www.linzess.com for more information about LINZESS. View Full Article

BRIGHT CHOICES 5.0 SETS NEW STANDARD FOR PRIVATE EXCHANGE TECHNOLOGY

December 13, 2012 - Liazon Corporation has introduced a newly improved platform for its Bright Choices Exchange. Bright Choices 5.0 combines the latest in cutting-edge technology, design best practices, and decision-support functions based upon years of actual user experience data. The award winning portal includes a streamlined user interface and comprehensive education section to further improve the consumer experience, as well as operational efficiencies to enhance the experience for Liazon's carrier and broker partners.

View Full Article

Independent Health Teams with Liazon for Private Benefits Exchange

December 6, 2012 - Independent Health has begun offering its innovative health care plans through Liazon's award-winning Bright Choices Exchange to employers. Bright Choices helps employers control the escalating cost of health care benefits while giving employees greater benefits choices. The program will be available to customers in Western New York beginning immediately.
View Full Article

Constella (linaclotide) approved in Europe for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in Adults

November 28, 2012 - Almirall, S.A. (ALM:MC) and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that the European Commission has granted marketing authorization to Constella (linaclotide 290mcg) for the symptomatic treatment of moderate to severe Irritable Bowel Syndrome with Constipation (IBS-C) in adults. This approval follows the positive recommendation received from the European Committee for Medicinal Products for Human Use (CHMP) in September. View Full Article

MVP HEALTH CARE LAUNCHES BENEFITS EXCHANGE POWERED BY BRIGHT CHOICES

November 28, 2012 - MVP Health Care has launched a new proprietary benefits exchange powered by Liazon's Bright Choices exchange technology. NuOptions(SM) helps employers control the escalating cost of health care benefits while giving employees greater benefits choices. The program is available immediately to businesses in New York, New Hampshire and Vermont.

View Full Article

Pfizer Acquires NextWave Pharmaceuticals, Inc.

November 28, 2012 - Pfizer Inc. (NYSE: PFE) today announced that it has completed its acquisition of NextWave Pharmaceuticals, Inc., a privately held, specialty pharmaceutical company focused on the development and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD). View Full Article

Blueprint Medicines Welcomes Daniel S. Lynch to its Board of Directors as Executive Chairman; Announces Permanent Appointment of Chris Varma, Ph.D. as Chief Executive Officer

November 13, 2012 - Blueprint Medicines, a company harnessing the understanding of the molecular blueprint of cancer to develop personalized, highly-selective cancer therapies, today announced the addition of Daniel S. Lynch as executive chairman of its board of directors. In addition, Blueprint Medicines announced that Chris Varma, Ph.D., founding president and chief executive officer of Blueprint Medicines and entrepreneur-inresidence (EIR) at Third Rock Ventures, has been appointed as permanent president and chief executive officer. View Full Article

New England Journal of Medicine Publishes Data from Topaz Pharmaceuticals Phase III Studies on Topical Ivermectin

November 1, 2012 - View Full Article

Ultragenyx Announces Completion of Phase 2 Study Enrollment for UX001 in Hereditary Inclusion Body Myopathy

October 30, 2012 - View Full Article

Aclaris Formed to Develop Novel Dermatology Treatment; Raises $21 Million in Series A Financing

October 24, 2012 - View Full Article

Ironwood and Astrazeneca Announce Linaclotide Collaboration for China

October 23, 2012 - View Full Article

Pfizer To Acquire NextWave Pharmaceuticals, Inc.

October 22, 2012 - Pfizer Inc. (NYSE: PFE) today announced its intention to acquire NextWave Pharmaceuticals, a privately held, specialty pharmaceutical company focused on the development and commercialization of unique products for the treatment of attention deficit/hyperactivity disorder (ADHD) and related central nervous system (CNS) disorders. View Full Article

Takeda to Acquire LigoCyte Pharmaceuticals, Inc.

October 5, 2012 - View Full Article

NextWave Pharmaceuticals Receives FDA Approval of Quillivant XR for Once-Daily Treatment of ADHD

October 1, 2012 - View Full Article

EnVivo Pharmaceuticals Named a "Fierce 15" Biotech Company for 2012

September 19, 2012 - The Scoop: EnVivo has tackled Alzheimer's disease--an area where most developers fear to tread. But instead of going after the amyloid beta hypothesis, the biotech is blazing a new path toward a potential therapy for one of the biggest unmet medical needs in the business.

"What our compound does," says CEO Kees Been, "is basically facilitate neuronal firing, the transmittal of the signal across neurons," with an eye to improving the cognitive abilities and clinical function of millions of people diagnosed with Alzheimer's. And the developers have data to back up their belief that the same approach will help patients suffering from schizophrenia. View Full Article

Mersana Therapeutics Named a "Fierce 15" Biotech Company for 2012

September 19, 2012 - View Full Article

Tetraphase Pharmaceuticals Announces Positive Phase 2 Data for Eravacycline (TP-434) in Patients with Complicated Intra-Abdominal Infections (cIAIs)

September 12, 2012 - Eravacycline cure rates compare favorably to ertapenem in the clinical treatment of cIAIs -
In the trial, eravacycline was well tolerated with low rates of gastrointestinal side effects -
Results support continued development of eravacycline for the treatment of serious infections caused by drug-resistant gram-negative pathogens View Full Article

Ironwood and Forest Announce FDA Approval of LINZESS (linaclotide) for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation

August 30, 2012 - Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) announced today that LINZESS (linaclotide) was approved by the U.S. Food and Drug Administration (FDA) as a once-daily treatment for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). View Full Article

Seeking to reinvent primary care, Iora Health to open Boston area medical practice

August 28, 2012 - Iora Health, a Cambridge startup aiming to "reinvent primary care" with a novel model for payment and delivery of care, plans to open its first Boston area primary care practice at the start of 2013, CEO Rushika Fernandopulle said in an interview. View Full Article

Liazon Debuts on INC. 500 with 2,417% Growth

August 21, 2012 - Liazon Corporation was recognized as one of Americas fastest-growing businesses today as it debuted on the Inc. 500, the annual ranking of the 500 fastest-growing private companies in the United States by Inc. Magazine. Receiving one of the most prestigious awards in business, the company boasted a 2,417% growth rate over the past three years and ranked #132 overall in its first time on the list. View Full Article

Sklice (ivermectin) Lotion, 0.5% Now Available in the US for Topical Treatment of Head Lice

August 20, 2012 - Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that Sklice (ivermectin) Lotion, 0.5% is now commercially available by prescription in U.S. pharmacies for the topical treatment of head lice infestations in patients 6 months of age and older, in the context of an overall lice management program.1 View Full Article

Proteostasis Therapeutics Presents Data at Multiple Scientific Conferences Highlighting Novel Approach to Neurodegenerative Diseases and Cystic Fibrosis

August 14, 2012 - Proteostasis Therapeutics, Inc., a company developing novel therapeutics that regulate protein homeostasis to improve outcomes for patients with neurodegenerative and orphan diseases, announced today that company scientists, founders and co-founders made the following presentations at scientific conferences in the last month highlighting progress with the Companys lead programs and the potential of its approach to developing disease modifying therapeutics: View Full Article

Liazon's Private Exchange Expands Aetna Offerings in Key Markets

August 8, 2012 - Liazon today announced that it is expanding its offering of Aetna health care plans available through its Bright Choices Exchange in several key markets on the East Coast. Bright Choices is Liazons market-leading private benefits exchange that is already serving tens of thousands of members through more than 2,000 employers. Businesses will be able to access the exchange through select insurance brokers in the New York, Connecticut, Philadelphia, Delaware and Western Pennsylvania markets. View Full Article

Adimab and Mersana Announce Antibody-Drug Conjugate Alliance

August 1, 2012 - Adimab, LLC, the technology leader in the discovery and optimization of fully human therapeutic antibodies, and Mersana Therapeutics, Inc., a next-generation antibody-drug conjugate (ADC) company, today announced the initiation of a joint effort to offer integrated antibody discovery and ADC technologies. The alliance is built to offer pharmaceutical companies seamless access to Adimabs world-class antibodies that have been specifically optimized for use in ADCs together with Mersanas Fleximer polymer and broad array of customizable linkers for attaching diverse, potent payloads. View Full Article

Mersana Therapeutics Raises $27M to Advance Fleximer Antibody-drug Conjugates

July 31, 2012 - Mersana Therapeutics, Inc. a biopharmaceutical company developing its Fleximer antibody-drug conjugate (ADC) platform and pipeline of small molecule Fleximer conjugates, announced today that it has closed a $27million Series A-1 financing led by new investor New Enterprise Associates (NEA). Participation in the round also included new investor Pfizer Venture Investments and existing investors Fidelity Biosciences, ProQuest Investments, Rho Ventures and Harris and Harris Group. View Full Article

Proteostasis Therapeutics Announces Expansion of Collaboration with The Scripps Research Institute to Broaden Cystic Fibrosis Program

July 26, 2012 - Proteostasis Therapeutics, Inc., a company developing novel therapeutics that regulate protein homeostasis to improve outcomes for patients with neurodegenerative and orphan diseases, announced today that it has expanded its collaboration with The Scripps Research Institute (TSRI) to encompass an additional funded research project focused on biology and the testing of small molecule modulators of protein folding and trafficking for the treatment of cystic fibrosis (CF). This expansion follows the Companys recently announced collaboration with the Cystic Fibrosis Foundation to research, develop, and commercialize therapies to treat patients with the most common mutation of the cystic fibrosis transmembrane conductance regulator (CFTR), Delta F508. View Full Article

Siteman Cancer Center at Barnes-Jewish and Washington University Begins Imaging with Viewray System

July 11, 2012 - Investigators at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, Missouri, have begun studying the imaging capabilities of an innovative radiation therapy system from ViewRay Incorporated. The ViewRay system is the first comprehensive image-guided radiation therapy system, providing a patented combination of simultaneous radiotherapy delivery and continuous magnetic resonance imaging (MRI) for the treatment of cancer. The Siteman Cancer Center is a national leader in the early adoption and use of advanced treatments for cancer patients. View Full Article

Ultragenyx Initiates Phase 2 Study of UX001 in Hereditary Inclusion Body Myopathy, a Rare Neuromuscular Disease

July 5, 2012 - Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced the dosing of the first two patients in a Phase 2 study of UX001 for hereditary inclusion body myopathy (HIBM). HIBM is a rare, severe, neuromuscular disease caused by sialic acid deficiency. UX001 is an extended-release oral tablet formulation of sialic acid (SA-ER) intended as a substrate replacement therapy for HIBM. View Full Article

Insmed Announces First Patient Dosed in TARGET-NTM Phase 2 Clinical Trial of ARIKACE

June 27, 2012 - Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the first patient has been dosed in the Company's U.S. phase 2 clinical study of ARIKACE (liposomal amikacin for inhalation) in patients with non-tuberculous mycobacterial (NTM) lung disease entitled TARGET-NTM (Treatment with ARIKACE to Realize Greater Efficacy Trial). View Full Article

Liazon's Bright Choices Benefits Exchange has been named winner of the Silver Web Health Award in the "Web-based Resource/Tool" category from the Web Health Awards

June 21, 2012 - Liazon's Bright Choices Benefits Exchange has been named winner of the Silver Web Health Award in the "Web-based Resource/Tool" category from the Web Health Awards. The awards, administered by the Health Information Resource Center, recognize the nation's best digital health resources. Bright Choices was judged against 600 entries, including those from innovators and industry-leaders such as WebMD, UnitedHealthcare and OptumHealth. View Full Article

ViewRay Receives FDA 510(k) Clearance for MRI-Guided Radiation Therapy System

May 30, 2012 - ViewRay Incorporated, a privately held medical device company, has received U.S. FDA 510(k) premarket notification clearance for its MRI-guided radiation therapy system. The ViewRay system features a unique combination of radiotherapy delivery and simultaneous magnetic resonance imaging (MRI) for the treatment of cancer. ViewRay's treatment planning and delivery software received 510(k) premarket notification clearance in 2011. View Full Article

Blueprint Medicines Welcomes Fidelity Biosciences to Investor Syndicate

May 24, 2012 - Blueprint Medicines today announced that new investor Fidelity Biosciences joined existing founding investor Third Rock Ventures in its previously announced $40 million Series A financing. View Full Article

FDA Advisory Committee Finds Data Support Effectiveness of Tafamidis Meglumine, Pfizers Novel Investigational Treatment for Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP)

May 24, 2012 - Pfizer Inc. (NYSE:PFE) announced today that the United States Food and Drug Administrations (FDA) Peripheral and Central Nervous System Drugs Advisory Committee voted on Pfizers clinical data package for tafamidis meglumine. Tafamidis is a novel, investigational, oral therapy for the treatment of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) in adult patients with symptomatic polyneuropathy to delay neurologic impairment. View Full Article

Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE In Patients With Non-tuberculous Mycobacterial Lung Disease

May 23, 2012 - Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that it has begun screening patients for its U.S. phase 2 clinical trial, Treatment with ARIKACE to Realize Greater Efficacy Trial (TARGET-NTM), of ARIKACE (liposomal amikacin for inhalation) in patients with non-tuberculous mycobacterial (NTM) lung disease.

View Full Article

Proteostasis Therapeutics Announces Collaboration with Cystic Fibrosis Foundation Therapeutics

May 7, 2012 - Proteostasis Therapeutics, Inc. (PTI), a company developing novel therapeutics that regulate protein homeostasis to improve outcomes for patients with neurodegenerative and orphan diseases, announced today that it has entered into a collaboration with Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation, to research, develop and commercialize therapies to treat patients with the most common cystic fibrosis mutation, Delta F508. View Full Article

Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease

May 1, 2012 - Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced results from a first-in-human, multi-center, Phase 1 study of UX001 in patients with hereditary inclusion body myopathy (HIBM) showing that UX001 was well-tolerated with an expected extended release profile on absorption after oral administration. View Full Article

Liazon Closes $18.2M in Funding to Expand Private Benefits Exchange

April 24, 2012 - Liazon, which operates the market-leading Bright Choices(R) private health benefits exchange, has closed $18.2 million in new funding from investors to expand nationwide and develop new products. Bessemer Venture Partners and Fidelity Biosciences led the round with follow-on funding from existing investors Bain Capital Ventures and Rand Capital, SBIC. View Full Article

Dartmouth Tests New Model For Primary Care in Hanover

April 11, 2012 - The partnership between the college, Dartmouth-Hitchcock and the for-profit Massachusetts-based health care company Iora Health, does what many experts working on health care reform have been advocating -- redesigning primary care with the goal of keeping patients healthy and out of hospital emergency rooms, which contribute to the high cost of care. View Full Article

Tetraphase Presents Data at ECCMID from Growing Portfolio of Next-Generation Antibiotic Candidates

April 2, 2012 - Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on next-generation antibiotics, announced today that it is presenting new results from studies that demonstrate the improved potency and pharmacokinetics of several of its newest discovery-stage tetracycline analogs. These data, which focus on significant gram-negative pathogens including Pseudomonas aeruginosa, and troublesome gram-positive respiratory pathogens were described in seven poster presentations at the 22nd European Congress of Clinical Microbiology and Infectious Disease (ECCMID) in London, UK.

View Full Article

Ultragenyx Granted Orphan Designations in Europe for Two Lead Product Candidates, UX001 for HIBM and UX003 for MPS 7

March 28, 2012 - Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the European Medicines Agency (EMA) has granted orphan drug designations for sialic acid for the treatment of hereditary inclusion body myopathy (HIBM) and recombinant human beta-glucuronidase for the treatment of mucopolysaccharidosis type 7 (MPS 7). View Full Article

ViewRay Closes Round of Series C Financing

March 13, 2012 - ViewRay Incorporated, a privately held medical device company, has closed the final tranche of a $45 million round of Series C venture capital financing. Institutional investors include Aisling Capital, Fidelity Biosciences, Kearny Venture Partners, OrbiMed Advisors and Siemens Venture Capital (SVC) GmbH. View Full Article

Ultragenyx Announces the Completion of the Phase 1 Clinical Study of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease

March 8, 2012 - Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the Phase 1 study of UX001 for hereditary inclusion body myopathy (HIBM) has been completed. View Full Article

Mersana Therapeutics Enters Collaboration with Endo Pharmaceuticals to Develop Next-generation Antibody-drug Conjugates

March 7, 2012 - Mersana Therapeutics, Inc. announced today that it has entered into a collaboration agreement with Endo Pharmaceuticals (Nasdaq: ENDP) to develop next-generation antibody-drug conjugates (ADCs). Mersanas proprietary conjugation technology is comprised of the Companys Fleximer polymer and a broad array of customizable linker chemistries for attaching diverse, potent payloads and targeted antibodies. Under this agreement, Endo will pay an upfront fee to Mersana for the right to utilize the Fleximer technology to develop novel ADC candidates against a single cancer target.
View Full Article

Ultragenyx Granted Orphan Drug Designation for UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7)

February 28, 2012 - Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the FDA Office of Orphan Products Development has granted orphan drug designation for UX003 for the treatment of MPS 7. View Full Article

BARDA Awards Contract Worth up to $67 Million for the Development of a Novel Tetraphase Antibiotic

February 16, 2012 - Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria, including multidrug-resistant (MDR) gram-negative pathogens, today announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded a contract worth up to $67 million for the development of TP-434, a potent new antibiotic effective against multidrug-resistant gram-negative pathogens and the lead product candidate in Tetraphase's clinical pipeline. Tetraphase will be working on this contract with Buffalo, NY-based CUBRC, Inc. View Full Article

Sanofi Announces FDA Approval of Sklice Lotion for the Treatment of Head Lice

February 7, 2012 - Sanofi announced today that the U.S. Food and Drug Administration (FDA) has approved Sklice (ivermectin) lotion, 0.5% for the topical treatment of head lice, in patients 6 months of age and older. Effective and well-tolerated, Sklice Lotion treats lice in most patients with a single 10-minute application of the lotion, without nit combing. View Full Article

Ultragenyx In-Licenses Therapeutic Program for Rare Genetic Disease Mucopolysaccharidosis Type 7 from St. Louis University

January 5, 2012 - Ultragenyx Pharmaceutical, Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced it has in-licensed an enzyme replacement therapy program from St. Louis University to treat mucopolysaccharidosis type 7 (MPS 7). The in-licensed program is a treatment for an ultra-rare genetic, metabolic disorder that results from the deficiency of the beta-glucuronidase (GUS) enzyme. Also known as Sly syndrome, the disorder was first identified in 1973 by William S. Sly, MD, a world-renowned researcher in inherited diseases, who is currently Professor and Chairman Emeritus, Department of Biochemistry and Molecular Biology, at St. Louis University School of Medicine. Dr. Sly will collaborate with Ultragenyx on the MPS 7 development program. View Full Article

Cornerstone Therapeutics Acquires Cardiokine

January 4, 2012 - Cornerstone Therapeutics (NASDAQ: CRTX), a specialty pharmaceutical company focused on acquiring, developing and commercializing proprietary products for the hospital and respiratory markets, today announced that it has acquired Cardiokine Inc., a specialty pharmaceutical company focused on developing hospital products for cardiovascular indications. The merger was effective Dec. 30, 2011. View Full Article

The New England Journal of Medicine Publishes Study Showing LigoCytes Norovirus Vaccine Demonstrates Protection Against Illness

December 8, 2011 - LigoCyte Pharmaceuticals, Inc. announced today that its experimental vaccine provided significant protection against norovirus infection and related gastrointestinal illness collectively known as acute gastroenteritis (AGE). Norovirus infection, sometimes referred to as "the stomach flu" is one of the most common causes of severe nausea, vomiting, abdominal cramps and diarrhea afflicting 21 million Americans annually and is an important contributor to gastrointestinal disease worldwide. This was the first time a vaccine has demonstrated protection against norovirus. View Full Article

Ultragenyx Appoints Tom Kassberg as Chief Business Officer and Announces Management Team

November 21, 2011 - Ultragenyx Pharmaceutical, Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that Tom Kassberg as joined the company as Chief Business Officer. Mr. Kassberg will be responsible for leading the companys business development and corporate strategic planning activities, as well as the human resources and legal affairs functions. Mr. Kassberg brings to Ultragenyx more than twenty years of experience in the pharmaceutical and biotechnology industries. View Full Article

Imagen Biotech Secures Up to $40 Million to Advance Ophthalmology Therapies

October 19, 2011 - Imagen Biotech, Inc. announced today that it has secured up to $40 million in Series A financing from SV Life Sciences, Novo Ventures, and Fidelity Biosciences to pursue the identification and development of breakthrough treatments for blinding diseases with high unmet medical needs, including dry age-related macular degeneration (dry AMD). View Full Article

NIAID Awards Contract Worth up to $36 Million for the Development of a Novel Tetraphase Antibiotic

October 19, 2011 - Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria, including multidrug-resistant (MDR) gram-negative pathogens, today announced that National Institutes of Healths (NIH) National Institute of Allergy and Infectious Diseases (NIAID) has awarded a contract worth up to $36 million for the development of TP-271, Tetraphases novel antibiotic for respiratory disease caused by bacterial biothreats and antibiotic-resistant public health pathogens. View Full Article

Ultragenyx Granted Orphan Drug Designation for UX001 SA-ER for the Treatment of Hereditary Inclusion Body Myopathy (HIBM)

October 5, 2011 - Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the FDA Office of Orphan Products Development has granted orphan drug designation for UX001 for the treatment of hereditary inclusion body myopathy (HIBM). View Full Article

Proteostasis Therapeutics' Scientific Advisory Board Chairman, F. Ulrich Hartl, M.D., D. Med, Receives Lasker Award for Basic Medical Research

September 15, 2011 - Proteostasis Therapeutics announced today that Franz]Ulrich Hartl, M.D., D. Med, Chairman of the Companyfs Scientific Advisory Board, has received the 2011 Albert Lasker Award for Basic Medical Research, for discoveries concerning the cellfs protein]folding machinery. Dr. Hartl, who is a Professor and Director of the Department of Cellular Biochemistry at Max Planck Institute of Biochemistry, was honored alongside Arthur L. Horwich, M.D., of Yale University School of Medicine. Protein folding is a major component of the Proteostasis Network, which regulates protein folding, trafficking, and clearance within cells to maintain protein homeostasis. View Full Article

Fluidnet Corporation Completes $25 Million Series C Financing

August 16, 2011 - Fluidnet Corporation (www.fluidnet.net), an innovator of advanced intravenous (IV) infusion systems, announced today it has closed a $25 million Series C Financing. The round of financing was led by new investor Fidelity Biosciences, which was joined by new investor SCP Vitalife Partners and current investors Cardinal Partners, Easterly Capital and Rockport Venture Partners. View Full Article

Ultragenyx Initiates Phase 1 Clinical Study of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Muscle Wasting Disease

August 15, 2011 - Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced the dosing of the first patient in a Phase 1 study of UX001 for hereditary inclusion body myopathy (HIBM). UX001 is an extended release formulation of sialic acid intended as a substrate replacement therapy for HIBM, a severe, progressive, genetic neuromuscular disease caused by sialic acid deficiency. UX001 is the first program from the company's pipeline to enter the clinic since its founding in 2010.

View Full Article

Ironwood and Forest Announce Submission of New Drug Application for Linaclotide for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Constipation

August 9, 2011 - Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) today announced they have recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for linaclotide, a guanylate cyclase type-C (GC-C) agonist, for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC). View Full Article

Allergan, Inc. to Acquire Privately Held Dermatologic Company, Vicept Therapeutics

July 19, 2011 - Vicept Therapeutics and Allergan, Inc. (NYSE: AGN) today announced that they have entered into a definitive agreement for Allergan to acquire all of the outstanding shares and assets of the privately-held dermatology company. The agreement, estimated to close in the third quarter of 2011, includes a $75 million cash up-front payment by Allergan plus up to an aggregate of $200 million in payments payable by Allergan contingent upon achieving certain future development and regulatory milestones plus additional payments contingent upon acquired products achieving certain sales milestones.
View Full Article

EnVivo Announces Initiation of Gamma Secretase Modulator Clinical Program in Alzheimers Disease

June 27, 2011 - EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, announced today that it recently initiated a Phase 1 clinical trial of EVP-0962, its potent and selective gamma secretase modulator (GSM), in healthy volunteers. The trial is a double-blind, ascending single and multiple dose study designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of EVP-0962. To date, EVP-0962 has shown promising activity in preclinical cellular and transgenic models of Alzheimers disease. View Full Article

Ultragenyx Announces Series A Financing

June 20, 2011 - Ultragenyx Pharmaceutical Inc. today announced the closing of a $45 million Series A financing to support the development of rare disease therapeutics. The co-lead investors are TPG Biotech and Fidelity Biosciences, joined by European investor HealthCap, and Pappas Ventures. This funding will advance multiple rare disease product programs in the pipeline, as well as the development of new product candidates and partnerships. The lead product, UX-001, a first-in-class therapy for treatment of Hereditary Inclusion Body Myopathy (HIBM), is expected to enter the clinic in 2011. View Full Article

Insmed's ARIKACE Demonstrates Sustained Benefit Through Six Cycles of Treatment for Cystic Fibrosis Patients With Pseudomonas Lung Infections

June 10, 2011 - Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced positive data through six treatment cycles (72 weeks total duration) of its Phase 2 clinical trial program for ARIKACE (liposomal amikacin for inhalation) in cystic fibrosis (CF) patients with Pseudomonas lung infections. The data were presented at the 34th European Cystic Fibrosis Conference in Hamburg, Germany, by Predrag Minic, M.D., Professor of Pediatrics and Head of Pediatrics Pulmonology Department, Mother and Child Health Institute, Belgrade, Serbia, and co-lead investigator of the study.

View Full Article

Hologic Acquires TCT International Co. Ltd., a Leading Distributor of Medical Products in China

June 1, 2011 - Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced it has acquired TCT International Co. Ltd. (TCT), a distributor of medical products in China, including Hologic's ThinPrep Pap Test, related instruments and other diagnostic and surgical products.

View Full Article

Proteostasis Therapeutics & Elan Form Drug Discovery Initiative

May 25, 2011 - Proteostasis Therapeutics (Proteostasis) and Elan Corporation (NYSE: ELN) today announced a strategic business relationship to advance Proteostasis platform for the discovery and development of disease-modifying, small molecule drugs and diagnostics for the treatment of neurodegenerative disorders such as Parkinsons, Huntingtons, multiple sclerosis and amyotrophic lateral sclerosis (ALS), and a broad array of dementia-related diseases including Alzheimers. View Full Article

EnVivo Announces Positive Phase 2b Clinical Data for EVP-6124 in Schizophrenia

May 17, 2011 - Comprehensive Data Analysis Expected to be Presented at Medical Conference Later this Year; EnVivo Advancing Program Based Upon Compelling Results

EnVivo Pharmaceuticals announced today positive topline results of its randomized, placebo-controlled Phase 2b clinical trial of EVP-6124, its potent, orally bioavailable and selective alpha-7 agonist, in patients with schizophrenia. The data showed that EVP-6124 had a clinically meaningful and statistically significant impact on patients overall cognition - the trials pre-specified primary endpoint - when taken in combination with second-generation antipsychotics and as measured by the full CogState overall cognitive index, or OCI (p=0.05 for all patients treated with EVP-6124 versus placebo.) This positive effect on the OCI was supported by a strong positive trend for improved cognition on the MCCB Battery of cognition tests, which were conducted on all U.S. patients in the trial. View Full Article

Tetraphase Presents Data Demonstrating Robust Activity and Dosing Flexibility of Intravenous and Oral Next-Generation Antibiotic Candidates Targeting Complicated, Multidrug-Resistant Pathogens

May 9, 2011 - Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on next-generation antibiotics, announced today that it is presenting new results of several studies designed to support the continued advancement of its lead antibiotic, TP-434, a potent new broad-spectrum intravenous (I.V.) antibiotic with oral stepdown potential effective against difficult-to-treat and multidrug-resistant pathogens. View Full Article

SciClone Acquires NovaMed Pharmaceuticals Further Establishing It as a Leading China-Focused Specialty Pharmaceutical Company

April 19, 2011 - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) ("Company") today announced that it has acquired NovaMed Pharmaceuticals Inc., ("NovaMed") a China-based specialty pharmaceutical company. The acquisition brings additional broad sales and marketing, as well as regulatory and extensive business capabilities and pharmaceutical assets in the regulatory approval stage to its growing and profitable China-focused specialty pharmaceutical business. SciClone believes this acquisition will further position it as a leader in the rapidly expanding pharmaceutical industry in China. View Full Article

Vicept Therapeutics Announces Positive Results from a Second Phase II Study of V-101 for the Treatment of Type I Rosacea (Erythematotelangiectatic Rosacea)

April 19, 2011 - Vicept Therapeutics, Inc. announced today positive results from a second Phase II clinical trial evaluating the dose-response relationship of two concentrations of V-101 cream, a topical cream for the treatment of Type I Rosacea (Erythematous Rosacea). The results demonstrated a statistically significant improvement (p= <0.01) in the primary endpoint, a reduction in facial erythema or redness, over a twelve hour period versus placebo cream in patients with erythematous rosacea. Further, V-101 demonstrated a safety profile similar to placebo cream. This is the second of two V-101 Phase II studies to achieve statistical significance in the primary endpoints. View Full Article

Tafamidis, An Oral, Investigational Compound For The Treatment Of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) Sustained A Slowing Of Disease Progression Over 30 Months

April 12, 2011 - Pfizer Inc. (NYSE: PFE) announced today data from an open-label extension study (Fx-006) of the pivotal Phase II/III (Fx-005) trial. This extension study evaluated the long-term clinical outcomes of tafamidis, a novel, oral, investigational compound being studied as a treatment for patients with Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP). TTR-FAP is a rare and fatal neurodegenerative disease affecting approximately 8,000 patients worldwide. These data showed that slowing of disease progression was sustained over 30 months. The data was presented in an oral session at the 63rd Annual Meeting of the American Academy of Neurology. View Full Article

Mersana Therapeutics Initiates Phase 1b Extension Study of XMT-1001 in Gastric Cancer and Non-Small Cell Lung Cancer

March 25, 2011 - Mersana Therapeutics today announced the initiation of a Phase 1b extension study with its lead cancer product, XMT-1001, a novel DNA topoisomerase I inhibitor based on the companys Fleximer polymer conjugate platform, in second-line gastric cancer and second-/third-line non-small cell lung cancer. View Full Article

Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE in Nontuberculous Mycobacteria Indication

March 21, 2011 - Insmed Incorporated (Nasdaq: INSMD), a biopharmaceutical company, announced today that the Company's Investigational New Drug Application (IND) to conduct a pivotal Phase 3 clinical trial of ARIKACE (liposomal amikacin for inhalation) in nontuberculous mycobacteria (NTM) lung infections has been cleared by the U.S. Food and Drug Administration (FDA). View Full Article

ViewRay Receives FDA 510(k) Marketing Clearance for Treatment Planning and Delivery Software

February 23, 2011 - ViewRay, Inc., a privately held medical device company, has received U.S. FDA marketing clearance for its radiotherapy treatment planning and delivery software. View Full Article

BD Announces Agreement to Acquire Accuri Cytometers, Inc.

February 7, 2011 - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it signed a definitive agreement to acquire Accuri Cytometers, Inc., an Ann Arbor, Michigan-based company that develops and manufactures personal flow cytometers for researchers. View Full Article

Tetraphase Appoints Patrick Horn, M.D., Ph.D., As Chief Medical Officer

January 24, 2011 - View Full Article

Vicept Therapeutics Announces Positive Phase II Data of V-101 for the Treatment of Type I Rosacea (Erythematotelangiectatic Rosacea)

January 10, 2011 - View Full Article

IRONWOOD AND PROTAGONIST ESTABLISH COLLABORATION FOR PEPTIDE DRUG DISCOVERY AND DEVELOPMENT

January 8, 2011 - View Full Article

WuXi PharmaTech Announces Third-Quarter 2010 Results

November 9, 2010 - View Full Article

IRONWOOD PHARMACEUTICALS PROVIDES THIRD QUARTER 2010 INVESTOR UPDATE

November 4, 2010 - Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today provided an update on its business activities for the third quarter of 2010. View Full Article

IRONWOOD AND FOREST ANNOUNCE POSITIVE LINACLOTIDE RESULTS FROM SECOND PHASE 3 TRIAL IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION

November 1, 2010 - View Full Article

Positive Results From LigoCyte's Norovirus Vaccine Challenge Study Presented at IDSA Annual Meeting

October 25, 2010 - View Full Article

ARIKACE DEMONSTRATES SUSTAINED BENEFIT IN MULTIPLE STUDIES AND OVER MULTIPLE CYCLES OF TREATMENT OF PSEUDOMONAS LUNG INFECTIONS IN CYSTIC FIBROSIS PATIENTS

October 21, 2010 - View Full Article

Tetraphase Pharmaceuticals Names Garen Bohlin to Board of Directors to Advance Strategic Interests and Broaden Corporate Development Goals

October 12, 2010 - View Full Article

Tetraphase Demonstrates that Novel Antibiotic, TP-434, is Effective Against Gram-negative Multidrug-resistant Pathogens in Preclinical Studies

September 15, 2010 - View Full Article

Tetraphase Named as One of the Fierce 15 Biotech Companies of 2010

September 15, 2010 - View Full Article

Tetraphase Presents New Clinical and Preclinical Data for Novel AntibioticTP-434 at 2010 ICAAC

September 13, 2010 - View Full Article

Tetraphase to Present Extensive Data on Novel Broad Spectrum Antibiotic TP-434 at ICAAC

September 9, 2010 - View Full Article

Pfizer to Acquire FoldRx Pharmaceuticals

September 1, 2010 - FoldRx Focused on First-in-Class, Disease Modifying, Oral Therapeutics to Treat Disease Caused by Protein Misfolding View Full Article

ViewRay Secures Series C Financing

August 25, 2010 - ViewRay, Inc., a privately held medical device company, has
secured $20 million in Series C financing led by new investor Siemens Venture Capital (SVC)
GmbH and joined by existing investors Aisling Capital, Fidelity Biosciences, Kearny Venture
Partners and OrbiMed Advisors. The funding is intended to move the ViewRay system, a unique
image-guided radiation therapy system now in the late stages of development, through the
process of commercialization and placement in major medical centers.* View Full Article

WuXi PharmaTech Announces Preliminary Second-Quarter 2010 Financial Highlights and Increases Full-Year 2010 Financial Guidance

July 15, 2010 - WuXi PharmaTech (Cayman) Inc. (NYSE:WX), a leading research and development outsourcing company serving the pharmaceutical,biotechnology, and medical device industries, with operations in China and the United States, today announced its preliminary financial highlights for second-quarter 2010. The full earnings results will be
announced on August 2, 2010. View Full Article

ENVIVO PHARMACEUTICALS ANNOUNCES SIGNIFICANT RESULTS FROM GSM TRANSGENIC MOUSE MODEL FOR ALZHEIMERS DISEASE

July 14, 2010 - EnVivo Pharmaceuticals today announced at the Alzheimers Association 2010 International Conference on Alzheimers Disease (ICAD) results from its proprietary gamma-secretase modulator (GSM) pre-clinical study. View Full Article

Accuri Cytometers Completes $6 Million Series E Financing

July 12, 2010 - Accuri Cytometers, Inc., a world leader in providing life science researchers with easy-to-use, cost-effective flow cytometers, today announced completion of a $6 million Series E preferred stock financing. View Full Article

Vicept Therapeutics Secures $10 Million to Complete Series A Funding; Company to Develop Lead Product for Rosacea and Other Topical Agents for the Treatment of Skin Disorders

June 30, 2010 - Vicept Therapeutics Inc., a privately held specialty biopharmaceutical company dedicated to developing the first effective topically applied therapy for erythema (facial redness) of rosacea, announced today that it has secured $10 million to complete a total $16 million Series A financing. The Series A was led by Vivo Ventures, Sofinnova Ventures and Fidelity Biosciences. Proceeds from the financing will be used to fund Phase I and II development of V-101, the companys lead investigational product for the treatment of rosacea, as well as a second product to treat various forms of bruising and purpura. View Full Article

Ikano Therapeutics in Exclusive Global Licensing Agreement for ITI-111

June 28, 2010 - Ikano Therapeutics Inc. (ITI) and Upsher-Smith Laboratories, Inc. announced today that they have concluded an exclusive global licensing agreement for ITI-111, ITIs midazolam nasal spray. Under the terms of the agreement, Upsher-Smith will assume responsibility for all further development and commercialization of the product, which has received Orphan Drug status for the treatment of acute repetitive seizures in patients with epilepsy. View Full Article

Mersana Initiates Phase 1 Clinical Trial for XMT-1107 in Oncology

June 23, 2010 - Mersana Therapeutics, a platform-based cancer therapeutics company, today announced that it has initiated a Phase 1 clinical trial to study the safety and pharmacokinetics of XMT-1107 in patients with refractory advanced solid tumors. XMT-1107 is a novel anti-angiogenic fumagillin analog that employs Mersanas Fleximer platform. Mersanas XMT-1001, a conjugate of Fleximer and camptothecin (CPT), is currently completing a Phase 1 study. View Full Article

ARIKACE DEMONSTRATES SUSTAINED BENEFIT IN THE TREATMENT OF CYSTIC FIBROSIS PATIENTS WHO HAVE PSEUDOMONAS LUNG INFECTIONS

June 17, 2010 - Transave announces positive Phase II results for once-daily ARIKACE in the treatment of cystic fibrosis patients who have pseudomonas lung infections, View Full Article

FoldRx Pharmaceuticals Secures $29 Million Financing

June 15, 2010 - FoldRx Pharmaceuticals, Inc. (FoldRx) today announced it has closed a $29 million financing to advance tafamidis to market. FoldRx has completed and previously reported the positive results of a pivotal trial of tafamidis as a disease modifying therapy for TTR amyloid polyneuropathy (ATTR-PN), a progressive and life-threatening genetic neurodegenerative disease that affects thousands of patients worldwide. New investors Novo Ventures and Morgenthaler Ventures join existing investors HealthCare Ventures, Fidelity Biosciences, TPG Biotechnology, Alta Partners, and Novartis Venture Funds. View Full Article

Centocor Ortho Biotech Inc. Acquires RespiVert Ltd., Strengthens Pulmonary Focus

June 1, 2010 - Centocor Ortho Biotech Inc. today announced that it has acquired RespiVert Ltd., a privately held drug discovery company focused on developing small-molecule, inhaled therapies for the treatment of pulmonary diseases. View Full Article

Tetraphase Closes $45 Million Series C Financing

June 1, 2010 - Tetraphase Pharmaceuticals, a clinical stage biopharmaceutical company utilizing breakthrough synthetic chemistry technology to discover and develop next-generation antibiotics, today announced that it has raised $45 million in a Series C financing. Excel Venture Management led the round with participation from existing investors CMEA Ventures, Fidelity Biosciences, Flagship Ventures, Mediphase Venture Partners and Skyline Ventures. View Full Article

Transave Issues Key Composition of Matter Patent for Arikace (TM)

May 24, 2010 - Transave Inc. today announced that the United States Patent and Trademark Office has issued an important composition of matter patent (U.S. Patent No. 7,718,189) for liposomal aminoglycoside formulations including its lead compound, ARIKACE (liposomal amikacin for inhalation). The company expects that the patent will provide exclusivity for ARIKACE until October 1, 2026. View Full Article

NeuroTherapeutics Pharma Closes $43 Million Series B Financing and Adds Four New Investors

May 20, 2010 - NeuroTherapeutics Pharma, Inc. (NTP), a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders, announced today that it closed a $43 million Series B financing. New investors include Fidelity Biosciences, MPM Capital and SR One, who co&#8208;led the transaction, and Pfizer, Inc. Existing investors Novo Ventures and Thomas McNerney & Partners also participated in the round. View Full Article

WuXi PharmaTech Announces First-Quarter 2010 Results

May 12, 2010 - WuXi PharmaTech (Cayman) Inc. (NYSE:WX), a leading research and development outsourcing company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States, today announced its financial results for first-quarter 2010. View Full Article

Envivo Initiates Phase IIB Alzheimer's Disease Trial for EVP-6124

May 11, 2010 - EnVivo Pharmaceuticals today announced the initiation and dosing of patients in a Phase IIb study of its EVP-6124 compound, a selective alpha-7 nicotinic agonist in patients with mild to moderate Alzheimers disease. The multi-center, dose ranging, placebo controlled, six-month study taking place in the U.S. and Europe is designed to determine the safety and efficacy of EVP-6124 in producing procognitive effects and improving the clinical condition of Alzheimers disease patients. View Full Article

Ironwood Pharmaceuticals Provides First Quarter 2010 Investor Update

May 11, 2010 - Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today provided an update on its business activities for the first quarter of 2010. View Full Article

Accuri and eBioscience Partner to Offer Complete Flow Cytometry Solutions

May 10, 2010 - Accuri Cytometers, Inc., the fastest growing life sciences company marketing and producing revolutionary bench-top flow cytometer systems, and eBioscience, the number two supplier of research flow cytometry reagents, today announced that they have entered into a worldwide co-marketing agreement. The collaboration is designed to offer scientists a better and more comprehensive solution for their flow cytometry research needs, harnessing the cost-effectiveness, ease-of-use, performance capabilities and accessibility of the Accuri C6 Flow Cytometer System with the market leading extensive line of high quality cytometer research reagents offered by eBioscience. View Full Article

FoldRx Pharmaceuticals Appoints Dr. Georges Gemayel as Executive Chairman

May 5, 2010 - FoldRx Pharmaceuticals, Inc. (FoldRx) today announced that Georges Gemayel, Ph.D., has been appointed full time Executive Chairman of the companys Board of Directors. Dr. Gemayel brings to the role more than 25 years of experience in successfully developing and commercializing drugs with several notable pharmaceutical and biotechnology companies. View Full Article

Ironwood and Forest Present Positive Linaclotide Results from Two Pivotal Phase 3 Trials in Patients with Chronic Constipation

May 3, 2010 - Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) today presented Phase 3 clinical trial results assessing the efficacy and safety of the investigational drug linaclotide in patients with chronic constipation (CC). Linaclotide is a guanylate cyclase type C (GC&#8208;C) agonist in Phase 3 clinical development for the treatment of irritable bowel syndrome with constipation (IBS&#8208;C) and CC. The data presented demonstrate that statistical significance versus placebo was achieved for the primary endpoint of 12&#8208;week complete spontaneous bowel movement (CSBM) overall responder for each of the two doses studied in each trial. View Full Article

Tetraphase Announces Participation in Session on New Treatments for Multidrug-Resistant Gram-Negative Bacteria at 2010 BIO International Convention

April 29, 2010 - Tetraphase Pharmaceuticals Inc., a biopharmaceutical company developing novel antibiotics based on proprietary synthetic chemistry technology, today announced that it will be participating in a session on drug discovery and development of novel treatments for drug-resistant infections, taking place at the 2010 BIO International Convention in Chicago. View Full Article

Data from LigoCyte's Clinical Studies of Norovirus VLP Vaccine Presented at 13th Annual Conference on Vaccine Research

April 28, 2010 - LigoCyte Pharmaceuticals, Inc., a private biopharmaceutical company focused on the development of innovative vaccine products, announced today that results from two Phase I studies of its norovirus virus-like particle (VLP) vaccine candidate were presented today at the 13th Annual Conference on Vaccine Research. Sponsored by the National Foundation of Infectious Diseases, the conference is being held in Bethesda, Maryland, from April 26-28, 2010. View Full Article

Charles River Laboratories and Wuxi PharmaTech to Combine Creating the First Global CRQ Offering Fully Integrated Early-Stage Drug Development Services to Clients Worldwide

April 26, 2010 - Charles River Laboratories International, Inc. (NYSE: CRL), a leading global provider of research models and associated services and of preclinical drug development services, and WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading drug research and development outsourcing company with expertise in discovery chemistry and with operations in China and the United States, today announced that they have signed a definitive agreement under which Charles River and WuXi will combine in a cash and stock transaction valued at approximately $1.6 billion. View Full Article

FoldRx Pharmaceuticals Presents at the XII International Symposium on Amyloidosis Meeting

April 21, 2010 - FoldRx Pharmaceuticals, Inc. (FoldRx) today announced that researchers presented results from the successful pivotal trial of tafamidis meglumine (tafamidis) at the XII International Symposium on Amyloidosis in Rome, Italy. Tafamidis, the companys lead compound, is being investigated as a disease modifying therapy for TTR amyloid polyneuropathy (ATTR-PN), a progressive and life-threatening neurodegenerative disease that affects an estimated 10,000 patients worldwide. View Full Article

Mersana Therapeutics Presents Data Demonstrating XMT-1001 Substantially Accumulates in Tumor and Results in Significantly Prolonged Drug Exposure

April 20, 2010 - Mersana Therapeutics, a platform-based cancer therapeutics company, announced today positive preclinical pharmacokinetic data for its lead development candidate, XMT-1001, which is currently in a Phase 1 clinical trial in patients with advanced solid tumors. The results were presented in a poster session at the AACR 101st Annual Meeting 2010 in Washington, DC, held April 17-21, 2010. View Full Article

FoldRx Pharmaceuticals to Present at the American Academy of Neurology (AAN) Annual Meeting

April 14, 2010 - FoldRx Pharmaceuticals, Inc. (FoldRx) today announced that researchers will present results from the successful pivotal trial of tafamidis meglumine (tafamidis) at the 62nd American Academy of Neurology (AAN) Annual Meeting in Toronto. Tafamidis, the companys lead compound, is being investigated as a disease modifying therapy for TTR amyloid polyneuropathy (ATTR-PN), a progressive and life-threatening neurodegenerative disease that affects an estimated 10,000 patients worldwide. View Full Article

Mersana Enters Research and Exclusive License Agreement with Teva Pharmaceuticals for the Development and Commercialization of XMT-1107

April 13, 2010 - Mersana Therapeutics, a platform-based cancer therapeutics company, today announced that it has entered into a research and exclusive license agreement with Teva Pharmaceutical Industries Ltd. to develop and commercialize XMT-1107, a novel fumagillin analog, for the treatment of all indications, including cancer. Mersana plans to initiate a Phase 1 clinical trial for XMT-1107 in the second quarter of 2010. XMT-1107 will be the companys second oncology product to enter the clinic. Mersanas XMT-1001, a conjugate of Fleximer and camptothecin (CPT), is currently completing a Phase 1 study. View Full Article

WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2009 Results

March 9, 2010 - WuXi PharmaTech (Cayman) Inc. (NYSE:WX), a leading research and development outsourcing company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States, today announced its financial results for fourth-quarter and full-year 2009.
View Full Article

WuXi PharmaTech Enters into Collaboration with J&JPRD, a division of Janssen Pharmaceutica for Preclinical Services and Training

March 1, 2010 - WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced it has reached an agreement with Johnson & Johnson Pharmaceutical Research & Development, a division of Janssen Pharmaceutica N.V. (JANSSEN), to collaborate in the area of preclinical services.

View Full Article


Underwriters Exercise Over-Allotment Option for Ironwood Pharmaceuticals' Initial Public Offering

February 16, 2010 - Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced that the underwriters of its February 2, 2010 initial public offering (IPO) have exercised their over-allotment option in full on an additional 2.5 million shares of Ironwoods Class A common stock. View Full Article

ViewRay Wins NorTech Innovation Award

February 16, 2010 - ViewRay, Inc., a privately held medical device company, has earned a NorTech Innovation Award for its advancements in radiation therapy technology for the treatment of cancer. ViewRay was honored for its unique combination of medical imaging and radiotherapy, which is designed to improve the effectiveness of cancer treatments. Radiation therapy is used to treat nearly two&#8208;thirds of todays cancer patients. View Full Article

Michael J. Fox Foundation Awards Research Grant to EnVivo as Part of Initiative Seeking New Parkinson's Disease Treatments

January 19, 2010 - EnVivo Pharmaceuticals, Inc. has been awarded a research grant by the Michael J. Fox Foundation for Parkinsons Research (MJFF). The grant will fund research as part of the foundations Therapeutics Development Initiative that seeks new treatments for Parkinsons disease. View Full Article

EnVivo Enters Phase 2B Trials for its EVP-6124 Compound in the Treatment of Schizophrenia

January 5, 2010 - EnVivo Pharmaceuticals today announced the initiation and dosing of patients in a Phase 2b study of its EVP-6124 compound, a selective alpha-7 nicotinic agonist in patients with schizophrenia. EnVivo is conducting the multi-center, dose ranging, placebo controlled, three-month study in the U.S. and Europe. View Full Article

Ironwood Pharmaceuticals Files Registration Statement for Initial Public Offering

November 20, 2009 - Ironwood Pharmaceuticals, Inc. today announced that it has filed a registration statement on Form-1 with the U.S. Securities and Exchange Commission (SEC) relating to the proposed initial public offering of shares of its Class A common stock. The number of shares to be offered and the price range for the offering have not yet been determined. View Full Article

Ikano Therapeutics Receives Orphan Drug Designation for Epilepsy Drug

November 9, 2009 - Ikano Therapeutics, Inc. (ITI) announced today that it has received orphan drug designation for midazolam in the acute treatment of certain forms of epileptic seizure known as cluster seizures or alternatively, as acute repetitive seizures. ITI has a nasally administered form of midazolam called ITI-111 in late stage clinical development that is aimed at the treatment of these specific seizure types in an outpatient setting where other routes of administration can be difficult or inappropriate. Orphan Drug status confers seven years of marketing exclusivity for medicines that meet specific criteria in the treatment of qualifying conditions and patient populations. View Full Article

Bioconnect Systems to Present First in Man Results for Optiflow Vascular Implant

October 27, 2009 - Bioconnect Systems, Inc. announced today that data from the Company's first clinical study will be presented this week at the ASN
Meeting in San Diego. Bioconnects implant platform, the Optiflow, enhances a surgeons ability to create precise vascular connections. The initial indication is the creation
of an arteriovenous fistula needed for vascular access in dialysis patients. View Full Article

Transave completes successful Phase II clinical program for Arikace in the treatment of psueomonas lung infections

October 17, 2009 - Transave Inc., today reported additional positive clinical trial results on its lead investigational drug, ARIKACE (liposomal amikacin for inhalation), an antibiotic that aims to treat chronic lung infections. The latest results along with previously reported data demonstrate significant clinical benefits and complete the companys Phase II program in two indications for the treatment of lung infections due to the bacterium, Pseudomonas aeruginosa in cystic fibrosis (CF) patients and non-CF bronchiectasis patients. View Full Article

Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009

September 10, 2009 - Tetraphase Pharmaceuticals Inc., a
biopharmaceutical company capitalizing on breakthrough synthetic chemistry technology
announced today that it will present three (3) posters and deliver a slide presentation on
the synthesis and antibacterial activity of analogs from several novel classes of antibiotics
to treat drug-resistant infections at the 49th Interscience Conference on Antimicrobial
Agents and Chemotherapy (ICAAC) in San Francisco, CA. View Full Article

Transave Enters Into Cooperative Research Agreement With NIH To Study ARIKACE In Nontuberculous Mycobacteria

July 29, 2009 - Transave Inc. announced today that it has entered into a cooperative research and development agreement with the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), to study ARIKACE (liposomal amikacin for inhalation) in patients with nontuberculous mycobacteria (NTM) lung infections. View Full Article

AccuriCytometers Completes $4 Million Series D Financing

July 13, 2009 - Accuri Cytometers, Inc. today announced the completion of a $4
million Series D financing. The financing included current investors Fidelity Biosciences, Flagship
Ventures, Baird Venture Partners and Arboretum Ventures, as well as the InvestMichigan! Program comanaged
by Credit Suisse. Accuri will use the proceeds from the Series D financing to provide additional
working and growth capital to support the rapid market acceptance of the Accuri C6 Flow Cytometer
System, a revolutionary product designed to bring the power of flow cytometry analysis to the laboratory
of every life science researcher, and the recently introduced Accuri CSampler, an optional accessory
that adds user-friendly automation to the C6 system. View Full Article

Transave Completes Enrollment In ARIKACE Phase II Bronchiectasis Study

April 21, 2009 - Transave, Inc., today reported completion of patient enrollment in a Phase II study evaluating the safety and efficacy of Arikace (liposomal amikacin for inhalation) in non-cystic fibrosis (CF) bronchiectasis patients. The results, which are expected to be available by mid-year, will shed new light on how this patient population responds to treatment. Presently, there are no approved treatments for the disease. View Full Article

ViewRay Incorporated Closes $15M Tranche of Series B Financing

April 14, 2009 - ViewRay Incorporated, a
medical device company, announces the close of the second tranche of their $25M Series
B financing. Funding was triggered by the companys achievement of a major milestone
towards the development of their image guided cancer therapy device, the Renaissance
System. The financing was led by OrbiMed Advisors and Fidelity Biosciences, and was
joined by Aisling Capital and Kearny Venture Partners. View Full Article

Ironwood and Collaborators Present Preclinical Data Demonstrating that Cyclic GMP Alleviates Intestinal Pain--Data Presented at ACG Annual Scientific Conference

October 6, 2008 - View Full Article

Proteostasis Therapeutics Secures a $45 Million Series A Financing to Develop Proteostasis Regulator Drugs

August 25, 2008 - Proteostasis Therapeutics, Inc. (PTI) today announced that it has secured $45 million in a Series A financing led by Fidelity Biosciences. View Full Article

ProteoStasis Therapeutics: Cultivating the next Big Idea company

August 24, 2008 - Boston.com discusses Fidelity Biosciences' recent investment in ProteoStasis Therapeutics. View Full Article

WuXi PharmaTech (NYSE: WX) Appoints Mr. Steven M. Hutchins as VP of Business Development

August 1, 2008 - August 1, 2008 Shanghai, China WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced that it has appointed Mr. Steven M. Hutchins as Vice President of Business Development. View Full Article

U.S. Genomics Awarded $9.1 Million Contract for Development of Advanced Biosensor by the U.S. Department of Homeland Security

July 16, 2008 - U.S. Genomics today announced the award of a $9.1 million contract by the U.S. Department of Homeland Security (DHS) Science and Technology Directorate. View Full Article

Accuri Cytometers Completes $13 Million Series C Financing

July 8, 2008 - Accuri Cytometers Inc., a life sciences company developing revolutionary bench-top flow cytometer systems, today announced the completion of a $13 million Series C financing led by Fidelity Biosciences and Flagship Ventures. View Full Article

FoldRx Technology Enables Discovery of Novel Therapeutic Approach for Treating Cystic Fibrosis

July 8, 2008 - FoldRx Pharmaceuticals, Inc. (FoldRx) today announced that it has discovered a series of novel drug prototypes that have shown potential in vitro to correct the protein-folding defect associated with cystic fibrosis (CF). View Full Article

Intranasal Therapeutics Names Jeffrey Edelson, MD,

July 8, 2008 - Intranasal Therapeutics, Inc. (ITI), a specialty pharmaceutical company focused on developing nasally delivered, preservative-free drug products, today announced a key executive addition to the companys leadership team. Jeff Edelson, MD, previously employed by Johnson & Johnson (J&J) as Vice President, Internal Medicine and Therapeutic Area Head - Novel Therapeutics, has joined ITI as Executive Vice President, R&D, and Chief Medical Officer. View Full Article

Accuri Cytometers Inc. to Distribute FCS Express

June 27, 2008 - De Novo Software, a leading provider of flow cytometry data analysis solutions, and Accuri Cytometers, a privately held manufacturer of innovative benchtop flow cytometry systems, announced today that they have entered into a licensing agreement providing for Accuri to distribute a customized version of De Novo Software's flagship product, FCS Express, with every Accuri C6 Flow Cytometer System. View Full Article

Transave Announces Positive Phase II Results for Once-Daily Arikace in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections

June 13, 2008 - Transave, Inc., today reported positive results from a Phase II clinical trial on its lead investigational drug, Arikace (liposomal amikacin for inhalation). The compound is being developed for the treatment of cystic fibrosis (CF) patients who have lung infections... View Full Article

U.S. Genomics Recognized for Outstanding Entrepreneurship

June 12, 2008 - U.S. Genomics Inc, a pioneer of single molecule biology technologies for the biodefense and life sciences industries, has been recognized by the NSF for outstanding entrepreneurship at its May NSF SBIR /STTR (Small Business Innovation Research/Small Business Technology Transfer) Phase II Grantee Conference. View Full Article

Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.

February 12, 2008 - Mersana, a cancer therapeutics company, announced today that Timothy B. Lowinger, Ph.D., has joined the company as Chief Scientific Officer. View Full Article

Methygene Exercises Right to Opt-Out of HDAC Neurodegenerative Collaboration with Envivo

February 6, 2008 - MethylGene Inc. (TSX:MYG) and EnVivo Pharmaceuticals today announced that MethylGene has exercised its right to opt-out of further funding in its collaboration with EnVivo signed in February 2005. EnVivo will continue to research and develop... View Full Article

Dr. Manuel Worcel Appointed CEO and President of Cardiokine

January 22, 2008 - Cardiokine, Inc., a privately held specialty pharmaceutical company focused on the development of drugs for the treatment of heart failure and related indications, today announced that Dr. Manuel Worcel has been appointed President and Chief Executive Officer. View Full Article

ViewRay Incorporated Raises $25 Million in Series B Financing

January 21, 2008 - ViewRay Incorporated (http://www.viewray.com/), a medical device manufacturer, announced today the close of a $25 million Series B financing. Founded in 2004, ViewRay Incorporated is focused on the development of a real-time magnetic resonance imaging (MRI)... View Full Article

Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors

January 3, 2008 - Mersana, a cancer therapeutics company, announced today the appointment of C. Boyd Clarke as Chairman of the Companys Board of Directors. Mr. Clarke is a senior biotechnology and pharmaceutical executive with a significant record of accomplishment over a 30-year industry career. View Full Article

WuXi Pharma Tech

December 14, 2007 - WuXi PharmaTech (NYSE: WX), China's premier provider of pharmaceutical R&D outsourcing services announced today that Governor Deval L. Patrick of the Commonwealth of Massachusetts, accompanied by other members of Massachusetts... View Full Article

Governor Patrick Highlights Progress on the Massachusetts-China Relationship

December 10, 2007 - Governor Deval Patrick today highlighted progress made on the Massachusetts-China relationship during the Commonwealths first governor-led trade mission to China in seven years, including agreements signed between life science and clean energy groups... View Full Article

$22 Million to Help Acorn Fund Heart Device

December 9, 2007 - A small New Brighton company that has developed a unique device to treat patients who have heart failure said Wednesday that it has secured $22 million in financing. View Full Article

Topaz Pharmaceuticals Receives $20 Million Series A Financing

December 3, 2007 - (HSMN NewsFeed)--Topaz Pharmaceuticals Inc., a pharmaceutical company dedicated to the health and well being of children, today announced that it has secured $20 million in Series A financing from Aisling Capital (New York) and Fidelity Biosciences (Boston). View Full Article

WuXi PharmaTech (NYSE:WX) CEO Honored with Ernst & Young Entrepreneur Of The Year China 2007 Award

October 29, 2007 - WuXi PharmaTech (NYSE: WX), China's premier provider of pharmaceutical R&D outsourcing services announced today that Dr. Ge Li, the company's Chairman and Chief Executive Officer received the Ernst & Young Entrepreneur Of The Year (EOY) China 2007 Award. View Full Article

WuXi PharmaTech (NYSE:WX) Ranked the 28th of Deloitte Technology Fast 50 China

October 26, 2007 - WuXi PharmaTech (NYSE: WX), China's premier provider of pharmaceutical R&D outsourcing services announced today that it has been ranked the 28th in the Deloitte Technology Fast 50 China program, a ranking of the 50 fastest growing technology companies in China. View Full Article

Favorable Pharmacokinetic & Safety Data Observed in First Clinical Trial of Novel Fleximer Anticancer Agent

October 24, 2007 - Mersana, a cancer therapeutics company, announced interim results of a Phase I study of its lead product candidate, XMT-1001, in patients with advanced solid tumors. The data was presented by Edward A. Sausville, M.D., Ph.D, Professor of Medicine and... View Full Article

Mersana Therapeutics Reports Phase I Results for XMT-1001 in Patients with Solid Tumors

October 24, 2007 - Mersana, a cancer therapeutics company, announced interim results of a Phase I study of its lead product candidate, XMT-1001, in patients with advanced solid tumors. The data was presented by Edward A. Sausville, M.D., Ph.D, Professor of Medicine and... View Full Article

EnVivo Pharmaceuticals Announces Progress on Major Drug Programs Focusing on Alzheimer's Schizophrenia and Huntington's Diseases

October 17, 2007 - EnVivo Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs for neurodegenerative diseases, today announced progress on several key programs for addressing Alzheimers, Schizophrenia and Huntingtons diseases. View Full Article

EnVivo Announces Hiring of Chief Medical Officer

September 25, 2007 - EnVivo Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs for neurodegenerative diseases, today announced the appointment of Dr.Dana C. Hilt as Senior Vice President and Chief Medical Officer. View Full Article

Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration

September 17, 2007 - Microbia, Inc. and Forest Laboratories, Inc. (NYSE: FRX), today announced that they have entered into a 50/50 partnership in the United States to co-develop and co-market Microbias first-in-class compound linaclotide. Linaclotide is currently being investigated... View Full Article

WuXi PharmaTech (NYSE:WX) Announces Closing of Initial Public Offering

August 14, 2007 - WuXi PharmaTech (Cayman) Inc. (NYSE: WX) ("WuXi PharmaTech"), the leading China-based pharmaceutical and biotechnology research and development outsourcing company in the growing global drug R&D outsourcing market, announced today the closing of its... View Full Article

FoldRX and Cystic Fibrosis Foundation Therapeutics Announce $22 Million Collaboration

August 13, 2007 - FoldRx Pharmaceuticals, Inc. (FoldRx) and Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the nonprofit affiliate of the Cystic Fibrosis Foundation, announced today that FoldRx will receive up to $22 million over five years to discover and develop... View Full Article

Mersana Therapeutics, Inc. Appoints Pharmaceutical Industry Veteran Nicholas G. Bacopoulos, Ph.D. to Board of Directors

July 12, 2007 - Mersana Therapeutics, a cancer therapeutics company, announced today the appointment of Nicholas G. Bacopoulos, Ph.D. to its Board of Directors. A 24-year industry veteran, Dr. Bacopoulos brings to Mersana extensive top-level management experience in the... View Full Article

BIOGEN IDEC AND CARDIOKINE PARTNER TO DEVELOP LIXIVAPTAN, A NOVEL VASOPRESSIN ANTAGONIST

July 2, 2007 - Biogen Idec (NASDAQ: BIIB) and Cardiokine, Inc., a privately-held specialty pharmaceutical company focused on the development of drugs for the treatment of heart failure and related indications, today announced the signing of an agreement to jointly develop lixivaptan, an... View Full Article

U.S. Genomics Recognized for Outstanding Entrepreneurship by the National Science Foundation (NSF)

June 12, 2007 - U.S. Genomics Inc, a pioneer of single molecule biology technologies for the biodefense and life sciences industries, has been recognized by the NSF for outstanding entrepreneurship at its May NSF SBIR /STTR (Small Business Innovation Research/Small Business... View Full Article

Mersana Therapeutics, Inc. Initiates Phase I Trial of Anti-Cancer Agent, XMT-1001, in Solid Tumors

May 30, 2007 - Mersana Therapeutics, a cancer therapeutics company, announced today that it has initiated a Phase I open-label, dose-escalation trial of its lead product candidate, XMT-1001, in patients with solid tumors. XMT-1001 is a polymer-based prodrug of... View Full Article

Microbia Announces Positive Phase 2 Results for its Investigational Compound Linaclotide

May 21, 2007 - Microbia today announced the presentation of data from a Phase 2 study in which linaclotide accelerated colonic transit and improved bowel function in patients with constipation-predominant irritable bowel syndrome (IBS-C). These data also showed... View Full Article

U. S. Genomics Awarded $8.6 Million for Phase III Bio-Defense Contract

May 15, 2007 - U.S. Genomics has been awarded an $8.6 million Phase III contract by the U.S. Department of Homeland Security (DHS) Science and Technology Directorate to continue development of the Company's sophisticated biological sensor for biodefense applications. Under the... View Full Article

Mersana Therapeutics, Inc. Announces the Appointment of Robert J. Fram, M.D. as Chief Medical Officer

May 11, 2007 - Mersana Therapeutics, a cancer therapeutics company, announced today the appointment of Robert J. Fram, M.D., F.A.C.P. in the newly created position of Chief Medical Officer. Dr. Fram will oversee all clinical and medical activities at the company as it moves forward with... View Full Article

U.S. Genomics Appoints Salamone to Its Board of Directors

May 8, 2007 - U.S. Genomics announced today that Salvatore J. Salamone, Ph.D., has joined the company's Board of Directors. Dr. Salamone is presently also Chairman and Chief Executive Officer of Saladax BioMedical Inc., a developer of chemotherapy monitoring... View Full Article

Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001 at American Association of Cancer Research Annual Meeting

April 13, 2007 - Mersana, a cancer therapeutics company, announced today that results of preclinical studies with its lead product candidate, XMT-1001, will be presented in two posters at the 2007 Annual Meeting of the American Association of Cancer Research (AACR) taking place... View Full Article

Bioconnect Systems Completes $8M Series A Financing

April 5, 2007 - (BUSINESS WIRE)--Bioconnect Systems, Inc. announced today that the company has raised $8 million in Series A financing. Bioconnects initial product platform, the Optiflow, enables surgeons to create precisely controlled connections throughout the body. View Full Article

Intranasal Therapeutics, Inc. Appoints Pharmaceutical Industry Veteran

April 4, 2007 - Intranasal Therapeutics, Inc. (ITI), a specialty pharmaceutical company focused on developing nasally delivered, preservative-free drug products, today announced the appointment of Peter F. Young as President and Chief Executive Officer. Mr. Young was most recently the President and CEO of AlphaVax, a privately held biotechnology company based in Research Triangle Park, NC. He will be based in ITIs corporate headquarters in Montvale, NJ. View Full Article

U.S. Genomics & The Biophysical Society Honor Howard C. Berg with Outstanding Investigator

March 5, 2007 - U.S. Genomics announced today that Dr. Howard C. Berg, the Herchel Smith Professor of Physics the Professor of Molecular and Cellular Biology and a Member of the Rowland Institute at Harvard University, is the recipient of the Biophysical Society's annual award for... View Full Article

U.S. Genomics & The Biophysical Society Honor Howard C. Berg with Outstanding Investigator

March 3, 2007 - U.S. Genomics announced today that Dr. Howard C. Berg, the Herchel Smith Professor of Physics the Professor of Molecular and Cellular Biology and a Member of the Rowland Institute at Harvard University, is the recipient of the Biophysical Society's annual award for... View Full Article

Quest Diagnostics Announces Licensing Agreement for Genetic Testing Technology

January 19, 2007 - In a move that promises to advance physicians' ability to widely screen for Fragile X Syndrome (FXS), the most common form of inherited mental retardation, Quest Diagnostics Incorporated (NYSE: DGX) today announced the signing of a worldwide license... View Full Article

U.S. Genomics and Northrop Grumman Sign Teaming Agreement

December 19, 2006 - U.S Genomics Inc. and the Northrop Grumman Corporation (NYSE: NOC) have signed a teaming agreement to work together to commercialize U.S. Genomics' single molecule detection technology. View Full Article

Intranasal Therapeutics, Inc. Adds Key Executives to Management Team

December 6, 2006 - Intranasal Therapeutics, Inc. (ITI), a specialty pharmaceutical company focused on developing nasally delivered, preservative-free drug products, announced today the appointment of two key executives to its management team. Franz F. Hefti, Ph.D., who has... View Full Article

Drug fights off disease but attracts investors

November 24, 2006 - Fledgling startup TetraPhase Pharmaceuticals Inc. has nailed down $25 million in a first round of venture financing toward developing treatments for drug-resistant infections. View Full Article

MethylGene and EnVivo Pharmaceuticals Form Collaboration with CHDI, Inc., in Support of HDAC Program for Huntingtons Disease

November 16, 2006 - MethylGene Inc. (TSX: MYG) with its collaborator EnVivo Pharmaceuticals, today announced that they have entered into a collaborative agreement with CHDI, Inc., a non-profit organization that is pursuing biotechnology approaches to rapidly discover and... View Full Article

EnVivo Pharmaceuticals Forms Research Collaboration With CHDI

October 25, 2006 - EnVivo Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs for neurodegenerative diseases, today announced it has established a research collaboration agreement with CHDI, Inc., a non-profit organization dedicated to... View Full Article

Linaclotide shown to improve symptoms of chronic constipation in phase 2A study

October 24, 2006 - Microbia today announced the presentation of data from a Phase 2a study demonstrating that treatment with linaclotide (MD-1100) improved bowel function in patients with chronic constipation. Treatment with linaclotide increased frequency of... View Full Article

U.S. Genomics and Lahey Clinic Announce Collaboration to Study the Role of microRNAs

October 17, 2006 - U.S Genomics Inc. and Lahey Clinic announce the signing of a discovery agreement to study the role microRNAs play in the development of urological cancers. The objective of the collaboration is to develop more accurate prognoses for bladder and... View Full Article

Envivo secures $24 million series C financing

October 4, 2006 - EnVivo Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs for neurodegenerative diseases, today announced it has secured $24 million in Series C financing led by existing investor Fidelity Biosciences. The company also said that... View Full Article

Transave, Inc. Appoints Renu Gupta, M.D. Chief Medical Officer

October 1, 2006 - Transave Inc., a biopharmaceutical company developing drugs for life-threatening lung diseases, today announced the appointment of Renu Gupta, M.D., as Executive Vice President of Development and Chief Medical Officer. View Full Article

TRANSAVES SLIT AMIKACIN IS GRANTED ORPHAN DRUG DESIGNATION BY THE EUROPEAN COMMISSION FOR THE TREATMENT OF PSEUDOMONAS AERUGINOSA LUNG INFECTIONS IN CYSTIC FIBROSIS

August 2, 2006 - Transave, Inc., a biopharmaceutical company focused on the development of inhaled, liposomal formulation of drugs for treating life threatening lung diseases, today announced that the European Agency for the Evaluation of Medicinal Products (EMEA) has granted... View Full Article

FoldRx Pharmaceuticals Closes $43 Million Series B Financing

May 30, 2006 - FoldRx Pharmaceuticals, Inc., a development-stage biotechnology company focused on protein misfolding diseases, announced today that it has successfully raised $43 million in a Series B financing. The funds will be used for the continued clinical development of... View Full Article

Envivo Expands Management Team As Company Prepares First Drugs For Clinical Trials

May 23, 2006 - EnVivo Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs for neurodegenerative diseases, today announced it has strengthened its management team with the appointment of Michael K. Ahlijanian, Ph.D. as Vice President, Research and... View Full Article

Microbia presents MD-1100 (Linaclotide Acetate) phase 1 results

May 23, 2006 - Microbia, Inc. today announced presentation of data from clinical and nonclinical studies with MD-1100 (linaclotide acetate), the Companys first-in-class investigational drug for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic... View Full Article

Cardiokine, Inc. Closes $50 Million Series B Financing

May 1, 2006 - Cardiokine, Inc., a specialty pharmaceutical company focused on the development of drugs for the treatment and prevention of heart failure and related cardiovascular and metabolic indications, announced today the closing of a $50 million Series B preferred share equity offering. View Full Article

Transave, Inc. Appoints Donald Hayden, Jr. Executive Chairman Of Its Board Of Directors

April 28, 2006 - Transave Inc., a biopharmaceutical company developing inhaled liposomal formulated drugs for treating life threatening lung disease, today announced the appointment of Donald J. Hayden, Jr. as executive chairman of the company's Board of Directors. Hayden is... View Full Article

Mersana Therapeutics, Inc. Appoints Key Members of Management Team

March 21, 2006 - Mersana, a privately-held cancer therapeutics company, announced today that Russell C. Petter, PhD, has joined the company as Vice President of Research and Ullrich S. Schwertschlag, MD, PhD as Vice President of Clinical Development. View Full Article

Microbia Raises $75 Million In Private Equity Financing To Advance Therapeutic Candidates Through Clinical Trials

February 27, 2006 - Microbia, Inc., an entrepreneurial pharmaceutical company with two internally discovered drug candidates in clinical trials, today announced it has raised $75 million in a series E private equity financing. In addition, the company announced the initiation of... View Full Article

Mersana Therapeutics -- $21M Series B Co-led by Fidelity Biosciences

November 9, 2005 - Mersana, a privately-held cancer therapeutics company announced today that it has completed an oversubscribed $21 million financing. Fidelity Biosciences and ProQuest Investments led the round, with Rho Ventures and the company's previous investors participating, including... View Full Article

Envivo Appoints Kees Been As Chief Executive Officer

June 27, 2005 - EnVivo Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on developing drugs for neurodegenerative diseases, announced today the appointment of Kees Been as Chief Executive Officer. View Full Article